Depomed Company Profile (NASDAQ:DEPO)

About Depomed (NASDAQ:DEPO)

Depomed logoDepomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Generic Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:DEPO
  • CUSIP: 24990810
  • Web: www.depomedinc.com
Capitalization:
  • Market Cap: $679.36 million
  • Outstanding Shares: 62,341,000
Average Prices:
  • 50 Day Moving Avg: $10.53
  • 200 Day Moving Avg: $13.39
  • 52 Week Range: $9.38 - $27.02
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -121.22
  • P/E Growth: 0.63
Sales & Book Value:
  • Annual Revenue: $441.56 million
  • Price / Sales: 1.54
  • Book Value: $3.69 per share
  • Price / Book: 2.96
Profitability:
  • EBIDTA: $125.09 million
  • Net Margins: -21.41%
  • Return on Equity: -25.33%
  • Return on Assets: -5.52%
Debt:
  • Debt-to-Equity Ratio: 2.71%
  • Current Ratio: 0.95%
  • Quick Ratio: 0.91%
Misc:
  • Average Volume: 1.57 million shs.
  • Beta: 1.15
  • Short Ratio: 6.99
 
Frequently Asked Questions for Depomed (NASDAQ:DEPO)

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed, Inc. (NASDAQ:DEPO) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.43) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.18. The firm earned $95 million during the quarter, compared to analyst estimates of $99.48 million. Depomed had a negative return on equity of 25.33% and a negative net margin of 21.41%. Depomed's quarterly revenue was down 9.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.04 earnings per share. View Depomed's Earnings History.

When will Depomed make its next earnings announcement?

Depomed is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Depomed.

Where is Depomed's stock going? Where will Depomed's stock price be in 2017?

8 analysts have issued 12 month target prices for Depomed's stock. Their forecasts range from $10.00 to $26.00. On average, they anticipate Depomed's stock price to reach $17.00 in the next twelve months. View Analyst Ratings for Depomed.

What are analysts saying about Depomed stock?

Here are some recent quotes from research analysts about Depomed stock:

  • 1. Cantor Fitzgerald analysts commented, "After the March 28 close, DEPO announced an agreement with Starboard that replaces CEO Jim Schoeneck as well as two incumbent board members. Guidance for 1Q17 revenue was also released, $95-100M vs. FactSet estimate." (3/29/2017)
  • 2. Janney Montgomery Scott analysts commented, "Recent developments in the 2013 patent litigation brought by DEPO against Purdue have resulted in DEPO filing an amended complaint claiming Purdue willfully violated its patents. The dispute pertains to DEPO's claim that Purdue's abuse-deterrent formulation of OxyContin, which was approved by the FDA on April 5, 2010 and subsequently commercialized, relies on inventions protected by patents for DEPO's Acuform?? drug delivery technology. With a potential royalty on cumulative net sales of $10 billion at stake, we have previously estimated, and continue to believe, a damage award of $200 million or more is possible, with little to no downside risk to DEPO in the process. We note our prior estimate did not contemplate an enhanced damage award that may result in a treble (3x) damages if DEPO prevails." (2/27/2017)
  • 3. Mizuho analysts commented, "We had expected some benefit from stocking in the quarter that did not materialize. Mgmt also lowered its FY:16 revenue guidance from $490-$520M to $480-$505M and tightened its earnings guidance towards the lower end of the prior range (non-GAAP adjusted Earnings are now $95-$105M, down from $95-$115M previously). We were modeling $488.8M in revenues and $84M in net income so the lowered guide is ultimately not that surprising. We will revisit our Buy rating and $23 PT after the earnings call. Product updates: Nucynta/ER sales of $71.9M (26.9% Y/Y growth) missed consensus estimates of $75.5M. Gralise revenues came in at $23.8M relative to $22.1M consensus, growing 13.7% Y/Y. We view this uptick as a sign that mgmt’s efforts to revitalize the brand have been somewhat effective. Zipsor sales of $6.8M (+13.8% Y/Y) beat consensus estimates of $6.4M due to the introduction of a 120 pill bottle (that led to a higher pill count or greater value per prescription). Cambia sales of $7.6M missed consensus estimates of $8.2M but the brand is still growing 11.2% Y/Y. Finally, Lazanda sales of $6.4M beat consensus estimates of $5.8M, and the brand grew 64.9% Y/Y. Activist updates: We expect an investor presentation from Starboard Value during its proxy solicitation period that could drive additional momentum in the stock." (8/4/2016)

Are investors shorting Depomed?

Depomed saw a drop in short interest in June. As of June 15th, there was short interest totalling 11,036,089 shares, a drop of 12.1% from the May 31st total of 12,559,484 shares. Based on an average trading volume of 1,531,458 shares, the short-interest ratio is currently 7.2 days. Approximately 18.0% of the company's stock are sold short.

Who are some of Depomed's key competitors?

Who are Depomed's key executives?

Depomed's management team includes the folowing people:

  • James P. Fogarty CPA, Chairman of the Board
  • Arthur J. Higgins, President, Chief Executive Officer, Director
  • August J. Moretti, Chief Financial Officer, Senior Vice President
  • Matthew M. Gosling, Senior Vice President, General Counsel
  • Sharon D. Larkin, Senior Vice President - Human Resources and Administration.
  • Gerd G. Kochendoerfer, Senior Vice President, Technical Development & Quality
  • Srinivas Gandham Rao M.D. Ph.D., Chief Medical Officer and Senior Vice President
  • Thadd M. Vargas, Senior Vice President - Business Development
  • Karen A. Dawes, Independent Director
  • Louis J. Lavigne Jr., Independent Director

Who owns Depomed stock?

Depomed's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include STARBOARD VALUE LP (8.70%), Deltec Asset Management LLC (1.64%), ING Groep NV (0.70%), Perkins Capital Management Inc. (0.12%), Creative Planning (0.06%) and Louisiana State Employees Retirement System (0.04%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

Who sold Depomed stock? Who is selling Depomed stock?

Depomed's stock was sold by a variety of institutional investors in the last quarter, including Public Employees Retirement Association of Colorado, Deltec Asset Management LLC, Capstone Asset Management Co., Creative Planning and Wellington Shields Capital Management LLC. Company insiders that have sold Depomed stock in the last year include August J Moretti and Thadd M Vargas. View Insider Buying and Selling for Depomed.

Who bought Depomed stock? Who is buying Depomed stock?

Depomed's stock was purchased by a variety of institutional investors in the last quarter, including ING Groep NV, Fox Run Management L.L.C., Aperio Group LLC, State of Alaska Department of Revenue, Perkins Capital Management Inc., Municipal Employees Retirement System of Michigan and Louisiana State Employees Retirement System. View Insider Buying and Selling for Depomed.

How do I buy Depomed stock?

Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Depomed's stock price today?

One share of Depomed stock can currently be purchased for approximately $10.91.


MarketBeat Community Rating for Depomed (NASDAQ DEPO)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  306 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  499
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Depomed (NASDAQ:DEPO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $17.00 (55.82% upside)

Analysts' Ratings History for Depomed (NASDAQ:DEPO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/16/2017Royal Bank Of CanadaSet Price TargetHold$13.00LowView Rating Details
5/25/2017MizuhoLower Price TargetNeutral$13.00 -> $11.00MediumView Rating Details
5/15/2017Cantor FitzgeraldSet Price TargetHold$14.00MediumView Rating Details
5/10/2017Piper Jaffray CompaniesUpgradeUnderweight -> Neutral$11.00 -> $10.00HighView Rating Details
4/11/2017Janney Montgomery ScottReiterated RatingBuy$26.00LowView Rating Details
3/30/2017JMP SecuritiesReiterated RatingOutperform$30.00 -> $16.00HighView Rating Details
2/18/2017Roth CapitalSet Price TargetBuy$24.00N/AView Rating Details
11/8/2016Leerink SwannSet Price TargetBuy$22.00N/AView Rating Details
3/24/2016Northland SecuritiesInitiated CoverageOutperform$22.00N/AView Rating Details
2/24/2016WallachBeth CapitalLower Price TargetBuy$33.00 -> $27.00N/AView Rating Details
12/3/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$21.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Depomed (NASDAQ:DEPO)
Earnings by Quarter for Depomed (NASDAQ:DEPO)
Earnings History by Quarter for Depomed (NASDAQ DEPO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017$0.09N/AView Earnings Details
5/9/2017Q1 2017($0.25)($0.43)$99.48 million$95.00 millionViewListenView Earnings Details
2/21/2017Q4 2016$0.36$0.48$123.00 million$123.90 millionViewListenView Earnings Details
11/7/2016Q3$0.35$0.28$127.22 million$111.00 millionViewListenView Earnings Details
8/3/2016Q2$0.26$0.27$118.20 million$116.70 millionViewListenView Earnings Details
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details
11/5/2014Q314($0.04)($0.01)$41.50 million$51.49 millionViewListenView Earnings Details
8/6/2014Q214($0.06)($0.03)$38.03 million$67.70 millionViewListenView Earnings Details
5/8/2014Q114$0.11($0.04)$53.57 million$76.50 millionViewListenView Earnings Details
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details
5/5/2011$1.05$1.77ViewN/AView Earnings Details
3/3/2011$0.06$0.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Depomed (NASDAQ:DEPO)
2017 EPS Consensus Estimate: ($0.20)
2018 EPS Consensus Estimate: $0.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.20)($0.23)
Q2 20172($0.32)($0.04)($0.18)
Q3 20172($0.05)$0.04($0.01)
Q4 20172$0.05$0.38$0.22
Q1 20181$0.03$0.03$0.03
Q2 20181$0.09$0.09$0.09
Q3 20181$0.12$0.12$0.12
Q4 20181$0.14$0.14$0.14
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Depomed (NASDAQ:DEPO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Depomed (NASDAQ:DEPO)
Insider Ownership Percentage: 2.59%
Institutional Ownership Percentage: 91.46%
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Institutional Ownership by Quarter for Depomed (NASDAQ:DEPO)
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2017Arthur J HigginsInsiderBuy15,000$9.92$148,800.00View SEC Filing  
11/14/2016August J MorettiCFOSell5,000$20.84$104,200.00View SEC Filing  
9/21/2016Thadd M VargasVPSell11,250$25.00$281,250.00View SEC Filing  
8/10/2016August J. MorettiCFOSell5,000$21.40$107,000.00View SEC Filing  
8/10/2016Thadd M VargasVPSell26,290$20.92$549,986.80View SEC Filing  
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00View SEC Filing  
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00View SEC Filing  
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.00View SEC Filing  
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00View SEC Filing  
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.00View SEC Filing  
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.50View SEC Filing  
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.00View SEC Filing  
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.40View SEC Filing  
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Depomed (NASDAQ:DEPO)
Latest Headlines for Depomed (NASDAQ:DEPO)
Source:
DateHeadline
americanbankingnews.com logoDepomed, Inc. (DEPO) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - July 25 at 8:03 AM
nytimes.com logoActivist Hedge Funds Pull Hard on the M&A Lever - The New York ... - New York Times
www.nytimes.com - July 25 at 3:34 AM
americanbankingnews.com logoDepomed, Inc. (DEPO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 24 at 10:38 PM
americanbankingnews.com logoDepomed (DEPO) vs. The Medicines (MDCO) Head-To-Head Comparison
www.americanbankingnews.com - July 24 at 8:22 PM
finance.yahoo.com logoETFs with exposure to Depomed, Inc. : July 21, 2017
finance.yahoo.com - July 21 at 7:35 PM
americanbankingnews.com logoCritical Review: Depomed (DEPO) & Merus Labs International (MSLI)
www.americanbankingnews.com - July 20 at 8:23 PM
americanbankingnews.com logoDepomed's (NASDAQ:DEPO) "Hold" Rating Reiterated at Royal Bank Of Canada
www.americanbankingnews.com - July 16 at 7:33 AM
americanbankingnews.com logoComparing Depomed (DEPO) and Hospira (HSP)
www.americanbankingnews.com - July 13 at 8:28 PM
streetinsider.com logoForm 8-K DEPOMED INC For: Jul 13 - StreetInsider.com
www.streetinsider.com - July 13 at 7:08 PM
finance.yahoo.com logoDepomed Announces Intent to Effect a Debt Refinancing
finance.yahoo.com - July 13 at 7:07 PM
finance.yahoo.com logoDepomed, Inc. -- Moody's assigns B3 CFR to Depomed; stable outlook
finance.yahoo.com - July 13 at 7:07 PM
americanbankingnews.com logoMerus Labs International (MSLI) & Depomed (NASDAQ:DEPO) Financial Analysis
www.americanbankingnews.com - July 13 at 8:34 AM
seekingalpha.com logoDepomed business development chief to retire at end of month with golden parachute
seekingalpha.com - July 13 at 7:26 AM
finance.yahoo.com logoDepomed, Inc. breached its 50 day moving average in a Bearish Manner : DEPO-US : July 12, 2017
finance.yahoo.com - July 12 at 6:28 PM
americanbankingnews.com logoReviewing Depomed (DEPO) & Merus Labs International (MSLI)
www.americanbankingnews.com - July 11 at 8:26 PM
finance.yahoo.com logoETFs with exposure to Depomed, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 5:49 PM
reuters.com logoBRIEF-Depomed chief medical officer Srinivas Rao resigns - Reuters
www.reuters.com - July 9 at 11:01 AM
reuters.com logoBRIEF-Depomed chief medical officer Srinivas Rao resigns
www.reuters.com - July 8 at 10:11 AM
americanbankingnews.com logoZacks: Analysts Anticipate Depomed, Inc. (DEPO) Will Post Quarterly Sales of $100.12 Million
www.americanbankingnews.com - July 6 at 9:16 AM
americanbankingnews.com logoCumberland Pharmaceuticals (CPIX) versus Depomed (NASDAQ:DEPO) Head to Head Analysis
www.americanbankingnews.com - July 5 at 8:27 AM
americanbankingnews.com logoZacks: Analysts Anticipate Depomed, Inc. (NASDAQ:DEPO) Will Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - July 5 at 12:22 AM
americanbankingnews.com logoDepomed, Inc. (DEPO) Sees Significant Drop in Short Interest
www.americanbankingnews.com - June 29 at 7:18 AM
americanbankingnews.com logoDepomed, Inc. (DEPO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 27 at 10:42 PM
finance.yahoo.com logoETFs with exposure to Depomed, Inc. : June 27, 2017
finance.yahoo.com - June 27 at 4:57 PM
americanbankingnews.com logoCritical Contrast: Depomed (DEPO) vs. Merus Labs International (MSLI)
www.americanbankingnews.com - June 26 at 2:26 PM
americanbankingnews.com logoCritical Contrast: Depomed (DEPO) and The Medicines Company (MDCO)
www.americanbankingnews.com - June 25 at 7:37 AM
finance.yahoo.com logoDepomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : June 23, 2017
finance.yahoo.com - June 23 at 5:19 PM
americanbankingnews.com logoDepomed's (DEPO) "Hold" Rating Reaffirmed at Royal Bank Of Canada
www.americanbankingnews.com - June 18 at 8:20 PM
finance.yahoo.com logoETFs with exposure to Depomed, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 5:28 PM
finance.yahoo.com logoDepomed, Inc. :DEPO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 5:41 PM
finance.yahoo.com logoDepomed, Inc. :DEPO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 5:41 PM
americanbankingnews.com logoArthur J. Higgins Acquires 15,000 Shares of Depomed, Inc. (DEPO) Stock
www.americanbankingnews.com - June 13 at 4:36 PM
investopedia.com logoOpioid Stocks Threatened by FDA Steps (ENDP, DEPO, INSY)
www.investopedia.com - June 12 at 5:40 PM
thestreet.com logoDepomed, Insys Shares Down After FDA Decision on Endo's Opana ER - TheStreet.com
www.thestreet.com - June 10 at 9:55 PM
americanbankingnews.com logoDepomed Inc (DEPO) Expected to Post Quarterly Sales of $100.12 Million
www.americanbankingnews.com - June 10 at 7:34 AM
americanbankingnews.com logo-$0.41 EPS Expected for Depomed Inc (DEPO) This Quarter
www.americanbankingnews.com - June 9 at 12:08 AM
americanbankingnews.com logoDepomed Inc (DEPO) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - June 4 at 8:36 PM
americanbankingnews.com logoDepomed Inc (DEPO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - June 2 at 12:46 PM
thestreet.com logoScott+Scott, Attorneys At Law, LLP Announces Investigation Into OneMain Holdings, Inc. (OMF)
www.thestreet.com - May 31 at 4:43 PM
prnewswire.com logoHow These Drug Makers Stocks are Faring? -- Depomed, Pernix Therapeutics ...
www.prnewswire.com - May 31 at 9:55 AM
americanbankingnews.com logoDepomed Inc (DEPO) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - May 25 at 9:52 PM
bizjournals.com logoShangPharma Innovation Appoints Mohamad Moghadam-Tabrizi as Senior Vice President of Business Development
www.bizjournals.com - May 24 at 12:36 PM
reuters.com logoBRIEF-Depomed announces corporate governance updates
www.reuters.com - May 22 at 11:59 AM
finance.yahoo.com logoDepomed Announces Corporate Governance Updates
finance.yahoo.com - May 22 at 11:59 AM
americanbankingnews.com logoDepomed Inc (DEPO) Given a $14.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 15 at 3:15 PM
americanbankingnews.com logoDepomed Inc (DEPO) Upgraded to Neutral by Piper Jaffray Companies
www.americanbankingnews.com - May 14 at 6:28 PM
americanbankingnews.com logo Brokerages Expect Depomed Inc (DEPO) Will Post Quarterly Sales of $110.54 Million
www.americanbankingnews.com - May 14 at 8:50 AM
americanbankingnews.com logoZacks: Analysts Anticipate Depomed Inc (DEPO) to Announce -$0.35 Earnings Per Share
www.americanbankingnews.com - May 12 at 8:28 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Rexahn Pharmaceuticals and Depomed
finance.yahoo.com - May 12 at 3:24 PM
streetinsider.com logoDepoMed Inc (DEPO) PT Lowered to $13 at RBC Capital; Magnitude of Reset was a Suprise - StreetInsider.com
www.streetinsider.com - May 11 at 5:21 PM

Social

Chart

Depomed (DEPO) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff